"Heparin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.
| Descriptor ID |
D006493
|
| MeSH Number(s) |
D09.698.373.400
|
| Concept/Terms |
Heparin- Heparin
- Unfractionated Heparin
- Heparin, Unfractionated
- Heparinic Acid
|
Below are MeSH descriptors whose meaning is more general than "Heparin".
Below are MeSH descriptors whose meaning is more specific than "Heparin".
This graph shows the total number of publications written about "Heparin" by people in this website by year, and whether "Heparin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 2 | 0 | 2 |
| 2004 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2012 | 0 | 2 | 2 |
| 2014 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Heparin" by people in Profiles.
-
Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial. Trials. 2014 Dec 20; 15:502.
-
Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients. JAMA. 2014 Nov 26; 312(20):2135-45.
-
The quality of antiplatelet and anticoagulant medication administration among ST-segment elevation myocardial infarction patients transferred for primary percutaneous coronary intervention. Am Heart J. 2014 Jun; 167(6):833-9.
-
Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb; 141(2 Suppl):e601S-e636S.
-
Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb; 141(2 Suppl):e227S-e277S.
-
Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. JACC Cardiovasc Interv. 2010 Jun; 3(6):669-77.
-
Effectiveness and cost effectiveness of thrombolysis in patients with acute pulmonary embolism. Curr Opin Pulm Med. 2008 Sep; 14(5):422-6.
-
Effectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism. Arch Intern Med. 2007 Jan 08; 167(1):74-80.
-
Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):429S-456S.
-
Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med. 1999 May 18; 130(10):800-9.